StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Ashish Bahety, Profitmart Securities

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byAshish Bahety, Profitmart SecuritiesHorizon: NA (inferred Intraday)21 Sept 2026, 12:27 pm ISTvia CNBC Awaaz.

Entry₹1,206Inferred
Target₹1,240
Total upside +2.82% (call closed)
Stop loss₹1,185-1.74% risk
At expiry₹1,202.121 Sept 2026, 3:05 pm
Expired-0.32%
Follow Ashish Bahety for new calls(15% target hit, 268 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 1 active Intraday pick this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Sept 2026
3 supporting0 opposing
Supports the BUY call (3)

3 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·21 Sept · today

Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine, in the private market in India. The agre

BSE · Company Update·18 Sept · 3d ago

(opens in new tab)

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 5d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Ashish Bahety, Profitmart Securities

Every call and its outcome